Drugs / CD19 specific Chimeric Antigen Receptor T Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05779930 | Oct 2025 → Dec 2030 expected | B-cell acute lymphoblastic leukemia | Nationwide Children's Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 specific Chimeric Antigen Receptor T Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05779930 ↗ |
| Modality | Cell therapy | “anti-CD19 CAR T cells manufactured on-site” NCT05779930 ↗ |
| Target | CD19 | “anti-CD19 CAR T cells” NCT05779930 ↗ |